Axsome Therapeutics announced that data from the SYMBRAVO (meloxicam and rizatriptan) clinical program will be presented at the 67th Annual Scientific Meeting of the American Headache Society. The presentations will cover the efficacy of SYMBRAVO based on baseline migraine-associated disability, long-term effects on headache burden and quality of life, and its efficacy and safety in patients with inadequate responses to oral CGRP inhibitors. These presentations are based on data from the INTERCEPT, MOVEMENT, and EMERGE trials, respectively.
This data release is important because it provides further insights into the efficacy and safety profile of SYMBRAVO, which is a recently approved treatment for acute migraine. The information presented at AHS will be crucial for neurologists and headache specialists in understanding how SYMBRAVO performs in different patient populations, including those with pre-existing migraine-related disability and those who have not responded to other therapies. This will allow for more informed treatment decisions and potentially expand the patient population benefiting from SYMBRAVO.
The data will detail the findings of three distinct trials evaluating SYMBRAVO’s performance in various aspects of migraine treatment. The INTERCEPT trial’s post-hoc analysis investigates how baseline migraine-related disability impacts SYMBRAVO’s efficacy. The MOVEMENT trial examines the long-term effects of SYMBRAVO on both headache burden and overall quality of life in patients. Finally, the EMERGE trial assesses the drug’s efficacy and safety specifically in patients who have experienced an inadequate response to oral CGRP inhibitors, a newer class of migraine medications.
This broader clinical evidence base for SYMBRAVO could enhance its market position and potentially drive wider adoption by healthcare professionals. The data could influence treatment guidelines and ultimately improve the lives of migraine sufferers by offering another effective treatment option, particularly for those who have had limited success with existing therapies. The detailed results from these presentations will be closely watched by clinicians, researchers, and investors alike, and could significantly impact the migraine treatment landscape.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
